This company has shut down. Dice Therapeutics is no longer operating — its last tracked round was a Post-IPO Equity in 2022.
Explore the Startup GraveyardDice Therapeutics is a clinical-stage biopharmaceutical company that makes medicines for chronic autoimmune and inflammatory diseases.
Dice Therapeutics has raised $345.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2022.
Dice Therapeutics's investors include RA Capital Management, Sands Capital Ventures, Janus Henderson Investors, OUP (Osage University Partners), Sanofi Ventures.
Dice Therapeutics is headquartered in San Francisco, United States.
Dice Therapeutics is a clinical-stage biopharmaceutical company that makes medicines for chronic autoimmune and inflammatory diseases.
Dice Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Dice Therapeutics — Funding & Investors." VCBacked, October 17, 2022, https://www.vcbacked.co/company/dice-therapeutics. Accessed August 14, 2026.
VCBacked. (2022). Dice Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/dice-therapeutics
{{cite web |title=Dice Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/dice-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated